BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 31665442)

  • 1. The Selective Progesterone Receptor Modulator Ulipristal Acetate Inhibits the Activity of the Glucocorticoid Receptor.
    Small B; Millard CEF; Kisanga EP; Burman A; Anam A; Flannery C; Al-Hendy A; Whirledge S
    J Clin Endocrinol Metab; 2020 Mar; 105(3):716-34. PubMed ID: 31665442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Place of ulipristal acetate in the management of uterine fibroids: Preoperative treatment or sequential treatment?
    Pourcelot AG; Capmas P; Fernandez H
    J Gynecol Obstet Hum Reprod; 2017 Mar; 46(3):249-254. PubMed ID: 28403922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Evaluation of Postmarketing Reports of Serious Idiosyncratic Liver Injury Associated with Ulipristal Acetate for the Treatment of Uterine Fibroids.
    Kang S; Brinker A; Jones SC; Dimick-Santos L; Avigan MI
    Drug Saf; 2020 Dec; 43(12):1267-1276. PubMed ID: 32647996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A-Kinase Anchoring Protein 13 (AKAP13) Augments Progesterone Signaling in Uterine Fibroid Cells.
    Ng SSM; Jorge S; Malik M; Britten J; Su SC; Armstrong CR; Brennan JT; Chang S; Baig KM; Driggers PH; Segars JH
    J Clin Endocrinol Metab; 2019 Mar; 104(3):970-980. PubMed ID: 30239831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ulipristal acetate for uterine fibroid-related symptoms.
    Puchar A; Luton D; Koskas M
    Drugs Today (Barc); 2015 Nov; 51(11):661-7. PubMed ID: 26744741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate.
    Donnez J; Donnez O; Dolmans MM
    Expert Opin Drug Saf; 2016 Dec; 15(12):1679-1686. PubMed ID: 27740868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ulipristal acetate versus placebo for fibroid treatment before surgery.
    Donnez J; Tatarchuk TF; Bouchard P; Puscasiu L; Zakharenko NF; Ivanova T; Ugocsai G; Mara M; Jilla MP; Bestel E; Terrill P; Osterloh I; Loumaye E;
    N Engl J Med; 2012 Feb; 366(5):409-20. PubMed ID: 22296075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic drug evaluation of ulipristal acetate for the treatment of uterine fibroids.
    Ferrero S; Vellone VG; Barra F
    Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):107-116. PubMed ID: 29250979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ulipristal Acetate: A Review in Symptomatic Uterine Fibroids.
    Garnock-Jones KP; Duggan ST
    Drugs; 2017 Oct; 77(15):1665-1675. PubMed ID: 28900897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term medical management of uterine fibroids with ulipristal acetate.
    Donnez J; Donnez O; Matule D; Ahrendt HJ; Hudecek R; Zatik J; Kasilovskiene Z; Dumitrascu MC; Fernandez H; Barlow DH; Bouchard P; Fauser BC; Bestel E; Loumaye E
    Fertil Steril; 2016 Jan; 105(1):165-173.e4. PubMed ID: 26477496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ulipristal acetate in the management of symptomatic uterine fibroids: facts and pending issues.
    Pérez-López FR
    Climacteric; 2015 Apr; 18(2):177-81. PubMed ID: 25390187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug safety evaluation of ulipristal acetate in the treatment of uterine fibroids.
    Tafi E; Scala C; Leone Roberti Maggiore U; Bizzarri N; Candiani M; Venturini PL; Ferrero S
    Expert Opin Drug Saf; 2015 Jun; 14(6):965-77. PubMed ID: 25772793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Selective progesterone receptor modulator (ulipristal acetate--a new option in the pharmacological treatment of uterine fibroids in women].
    Szamatowicz M; Kotarski J
    Ginekol Pol; 2013 Mar; 84(3):219-22. PubMed ID: 23700851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Applicability of selective progesterone receptor modulators in the treatment of uterine leiomyomata and their future role in the field of gynecology].
    Brazert M; Korman MP; Pawelczyk LA
    Ginekol Pol; 2013 Sep; 84(9):794-800. PubMed ID: 24191519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EC313-a tissue selective SPRM reduces the growth and proliferation of uterine fibroids in a human uterine fibroid tissue xenograft model.
    Nair HB; Santhamma B; Dileep KV; Binkley P; Acosta K; Zhang KYJ; Schenken R; Nickisch K
    Sci Rep; 2019 Nov; 9(1):17279. PubMed ID: 31754172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Ulipristal Acetate for the Management of Fibroid-Related Acute Abnormal Uterine Bleeding.
    Arendas K; Leyland NA
    J Obstet Gynaecol Can; 2016 Jan; 38(1):80-3. PubMed ID: 26872761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ulipristal acetate for use in moderate to severe symptoms of uterine fibroids.
    Talaulikar VS; Manyonda I
    Womens Health (Lond); 2014 Nov; 10(6):565-70. PubMed ID: 25482483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids.
    Donnez J; Hudecek R; Donnez O; Matule D; Arhendt HJ; Zatik J; Kasilovskiene Z; Dumitrascu MC; Fernandez H; Barlow DH; Bouchard P; Fauser BC; Bestel E; Terrill P; Osterloh I; Loumaye E
    Fertil Steril; 2015 Feb; 103(2):519-27.e3. PubMed ID: 25542821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ulipristal acetate: a novel option for the medical management of symptomatic uterine fibroids.
    Talaulikar VS; Manyonda IT
    Adv Ther; 2012 Aug; 29(8):655-63. PubMed ID: 22903240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucocorticoids suppress hypoxia-induced COX-2 and hypoxia inducible factor-1α expression through the induction of glucocorticoid-induced leucine zipper.
    Lim W; Park C; Shim MK; Lee YH; Lee YM; Lee Y
    Br J Pharmacol; 2014 Feb; 171(3):735-45. PubMed ID: 24172143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.